Pathiraja, et al. Supp. Fig. S1

Pathiraja, et al. Supp. Fig. S1 TRIM24 expression in TCGA BRCA A B Top 30% vs. Bottom 70% p-value: 1.32e-07 log2 FC (Invasive carcinoma/normal) p-value: 1.46e-08; Odds ratio: 0.43 p-value: 0.047; odds ratio: 1.40 p-value: 3.8e-04; Odds ratio: 1.98 Paired Samples • Fold change > 0 for 78 of 106 (73%) patients with paired profiles • 40 out of 106 (37.8%) patients have fold change > 1.5 p-value: 0.03; Odds ratio: 1.78 Key: LumA: ER+, PR+, HER2- LumB: ER+, PR+, HER2+ HER2: ER-, PR-, HER2+ Basal: ER-, PR-, HER2-

Pathiraja, et al. Supp. Fig. S2 A * *** (n =3) B

Pathiraja, et al. Supp. Fig. S3 Control TRIM24-1 TRIM24-2

Pathiraja, et al. Supp. Fig. S4 A B C

Pathiraja, et al. Supp. Fig. S5 MCF7 MDA-MB-231 *** *** *** siTRIM24 siTRIM24 siCtrl siCtrl TRIM24 Actin SKBR3 siTRIM24 siCtrl

Pathiraja, et al. Supp. Fig. S6 A B Control Control TRIM24-1 TRIM24-1 C TRIM24-2 TRIM24-2 D E F G H

Pathiraja, et al. Supp. Fig. S1

Pathiraja, et al. Supp. Fig. S1

Presentation Transcript

Supp. Fig 1

Supp Fig. 1

Fig. S1

Tholen et al ., Sup . Fig. S1

Fig S1

Supp. Fig.3

Supp. Fig.2

Fig. S1; Ritter et al. 2010

Fig. S1

Miao et al., Fig. S1

Supp. Fig. 1

Supplemental Fig. S1 Awano et al

Fig. S1. Ki et al .,

Fig. S1. Weng et al.

Fig. S1. (Zhu et al.)

Fig. S1 . Lee. et. al.

Fig. S1 . Okubo et al.

Supplemental Fig. S1. Nishimura et al. PMB

Teng et al. Fig. S1

Supplemental Fig. S1 Koma et al.